STAAR Surgical Company

Equities

STAA

US8523123052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
41.53 ^USD	+2.29%		+0.90%	+33.07%

May. 08	Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating	MT
May. 08	Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating	MT

STAAR Surgical Company Reiterates Earnings Guidance for the Fiscal Year 2024

May 07, 2024 at 04:03 pm EDT

STAAR Surgical Company reiterated earnings guidance for the fiscal year 2024. For fiscal 2024, the company reiterating net sales outlook range of $335 million to $340 million and expect, based on current trends, to be at the higher end of the range.

Latest news about STAAR Surgical Company

Mizuho Adjusts STAAR Surgical's Price Target to $55 From $53, Keeps Buy Rating	May. 08	MT
Morgan Stanley Raises Price Target on STAAR Surgical to $50 From $35, Keeps Equalweight Rating	May. 08	MT
Transcript : STAAR Surgical Company, Q1 2024 Earnings Call, May 07, 2024	May. 07
STAAR Surgical Company Reports Earnings Results for the First Quarter Ended March 29, 2024	May. 07	CI
STAAR Surgical Company Reiterates Earnings Guidance for the Fiscal Year 2024	May. 07	CI
STAAR Surgical Company Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision	May. 07	CI
STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel	May. 01	CI
Mizuho Adjusts Price Target on STAAR Surgical to $53 From $45, Maintains Buy Rating	Apr. 11	MT
Canaccord Genuity Raises Price Target on STAAR Surgical to $46 From $32, Maintains Hold Rating	Apr. 08	MT
STAAR Surgical Shares Jump After Reporting Preliminary Fiscal Q1 Sales	Apr. 04	MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Thursday	Apr. 04	MT
STAAR Surgical Reports Preliminary Fiscal Q1 Sales; Updates Fiscal 2024 Sales Outlook -- Shares Jump Pre-Bell	Apr. 04	MT
STAAR Surgical Company Provides Sales Guidance for the First Quarter Ended March 29, 2024	Apr. 04	CI
STAAR Surgical Unveils New EVO ICL Data and Latest Innovation for 2024	Apr. 02	CI
STAAR Surgical Company Announces Board Changes	Mar. 12	CI
North American Morning Briefing : Inflation Data -2-	Mar. 12	DJ
Stifel Upgrades STAAR Surgical to Buy From Hold, Raises Price Target to $50 From $30	Mar. 11	MT
Mizuho Securities Adjusts Price Target on STAAR Surgical to $45 From $50, Keeps Buy Rating	Feb. 28	MT
Piper Sandler Cuts STAAR Surgical Price Target to $33 From $40, Maintains Neutral Rating	Feb. 27	MT
STAAR Surgical Q4 Earnings, Revenue Rise	Feb. 26	MT
Transcript : STAAR Surgical Company, Q4 2023 Earnings Call, Feb 26, 2024	Feb. 26
STAAR Surgical Company Affirms Earnings Guidance for the Fiscal Year 2024	Feb. 26	CI
STAAR Surgical Company Reports Earnings Results for the Full Year Ended December 29, 2023	Feb. 26	CI
STAAR Surgical Company Reports Earnings Results for the Fourth Quarter and Full Year Ended December 29, 2023	Feb. 26	CI
Earnings Flash (STAA) STAAR SURGICAL COMPANY Posts Q4 Revenue $76.3M, vs. Street Est of $75.8M	Feb. 26	MT

Chart STAAR Surgical Company

Duration

Period

More charts

Company Profile

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Companyâs EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-06-20 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for STAAR Surgical Company

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

41.53 USD

Average target price

52.31 USD

Spread / Average Target

+25.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
STAAR SURGICAL COMPANY	+33.07%	2.04B
ABBOTT LABORATORIES	-7.16%	178B
MEDTRONIC PLC	-1.23%	107B
BECTON, DICKINSON AND COMPANY	-4.86%	67.04B
DEXCOM, INC.	-4.28%	47.24B
CENCORA, INC.	+10.32%	44.62B
HOYA CORPORATION	+8.14%	42.5B
METTLER-TOLEDO INTERNATIONAL, INC.	+15.76%	29.99B
TERUMO CORPORATION	+15.53%	25.22B
WEST PHARMACEUTICAL SERVICES, INC.	-5.88%	24.14B

Other Medical Equipment, Supplies & Distribution